A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

RecruitingOBSERVATIONAL
Enrollment

1,150

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 14, 2027

Conditions
Head and Neck CancerCervical CancerNon Small Cell Lung CancerHPV16 Related CancersSarcomaUveal MelanomaNUT Carcinoma
Interventions
DIAGNOSTIC_TEST

Tumor and HLA Profiling

HLA genotyping and tumor tissue profiling for certain tumor-associated antigens and HLA LOH.

Trial Locations (21)

10032

RECRUITING

Columbia University Herbert Irving Comprehensive Cancer Center, New York

15224

RECRUITING

Allegheny Hospitals Network, Pittsburgh

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

32806

RECRUITING

Orlando Health, Orlando

33021

RECRUITING

Memorial Healthcare System, Hollywood

33136

RECRUITING

University of Miami, Sylvester Comprehensive Cancer Center, Miami

33606

RECRUITING

University of South Florida, Tampa

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

40202

RECRUITING

Norton Cancer Institute, Louisville

44195

RECRUITING

The Cleveland Clinic, Cleveland

45242

RECRUITING

Oncology Hematology Care, Cincinnati

48201

RECRUITING

Karmanos Cancer Institute, Detroit

55455

RECRUITING

University of Minnesota, Masonic Cancer Center, Minneapolis

60637

RECRUITING

University of Chicago, Chicago

73104

RECRUITING

OU Health Stephenson Cancer Center, Oklahoma City

77030

RECRUITING

Baylor College of Medicine, Houston

85258

RECRUITING

HonorHealth Research and Innovation Institute, Scottsdale

92037

RECRUITING

University of California San Diego, San Diego

97213

RECRUITING

Providence Cancer Institute Franz Clinic, Portland

06510

RECRUITING

Yale Cancer Center, New Haven

All Listed Sponsors
lead

TScan Therapeutics, Inc.

INDUSTRY